Skip to main content

Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada

Journal: JAMA New Open
Lead Author: Buchan et al.
Original date of publication: 06/01/2022
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9233237/

Summary Context

Notes higher rates of heart damage in young males, 3 days post vaccination. Urges caution and to consider timing to reduce such damage.

Comments

This article is copyrighted by Health Freedom Defense Fund, Inc.
Visit our Re-post guidelines

This study compiled information in Canada about the rates of myocarditis and pericarditis and found troubling signals. Also noted mixing doses was associated with higher damaging events. Rates of myo- or pericarditis were higher when 2nd dose given within 30 days of first dose.Of almost 300 reports, 76% were males and 69% were after second dose.

Abstract or Results, Key Passages

“The findings of this population-based cohort study of Ontario adolescents and adults with myocarditis or pericarditis following mRNA COVID-19 vaccination suggest that vaccine products and interdose intervals, in addition to age and sex, may be associated with the risk of myocarditis or pericarditis after receipt of these vaccines. Vaccination program strategies, such as age-based product considerations and longer interdose intervals, may reduce the risk of myocarditis or pericarditis following receipt of mRNA vaccines.”


Keywords: adverse eventsCardiac eventscovid vaccinemRNAmyocarditis
Full Author List: Sarah A Buchan, Chi Yon Seo, Caitlin Johnson, Sarah Alley, Jeffrey C Kwong, Sharifa Nasreen, Andrew Calzavara , Diane Lu, Tara M Harris, Kelly Yu, Sarah E Wilson